


# Nephrology Group

Publications:

28

Q1:

15



## RESEARCH ACTIVITY

### ■ Doctoral theses

**Márquez Expósito L.** Papel del ligan-  
do no canónico de NOTCH pareci-  
do a Delta 1 (DLK1) en el daño renal  
experimental[dissertation]. Madrid: UAM:  
2021(09/07/2021).

Directors: Ruiz Ortega M,  
Rodrigues Díez R.


### ■ Publications

- Alonso-Pérez E, Forne C, Soro M, Valls M, Man-  
ganelli AG, Valdivielso JM. Health care costs in

patients with and without secondary hyperparathyroidism in Spain. *Adv Ther*. 2021; 38(10): 5333-44. Article. IF: 4.07; Q2

- Ávila-Carrasco L, García-Mayorga EA, Díaz-Ávila DL, Garza-Veloz I, Martínez-Fierro ML, González-Mateo GT. Potential therapeutic effects of natural plant compounds in kidney disease. *Molecules*. 2021; 26(20): 6096. Review. IF: 4.927; Q2

- Bermúdez-López M, Perpiñan H, Amigo N, Castro E, Alonso N, Mauricio D, Fernández E, Valdivielso JM. Advanced lipoprotein parameters could better explain atherosclerosis in non-diabetic chronic kidney disease patients. *Clin Kidney J*. 2021; 14(12): 2591-9. Article. IF: 5.86; Q1
- Buxeda A, Arias-Cabralles C, Pérez-Sáez MJ, Ca-  
cho J, Pelegrín SC, Melilli E, Aladren MJ, Galea-



- no C, Lorenzo I, Mazuecos A, Saura IM, Franco A, Ruiz-Fuentes MD, Sánchez-Camara LA, Siverio O, Martín ML, González-García E, López V, Martín-Moreno PL, Moina I, Berrio EM, Moreso F, Portoles JM, Santana-Estupinan R, Zarraga S, Canal C, Sánchez-Álvarez E, Pascual J, Crespo M. Use and safety of remdesivir in kidney transplant recipients with COVID-19. *Kidney Int Rep.* 2021; 6(9): 2303-15. Article. IF: 6.234; Q1
- Caravaca-Fontán F, Trujillo H, Alonso M, Díaz-Encarnación M, Cabello V, Ariceta G, Quintana LF, Marco H, Barros X, Ramos N, Rodríguez-Mendiola N, Cruz S, Fernández-Juárez G, Rodríguez E, de la Cerda F, de Jose AP, López I, Fernández L, Gómez VP, Ávila A, Bravo L, Lumbreras J, Allende N, de la Nieta MDS, Olea T, Melgosa M, Huerta A, Miquel R, Mon C, Fraga G, de Lorenzo A, Draibe J, González F, Shabaka A, Illanes ML, Calvo C, Oviedo V, Da Silva I, de Jorge EG, Carravaca F, Praga M. Validation of a histologic scoring index for C3 glomerulopathy. *Am J Kidney Dis.* 2021; 77(5): 684-95. Article. IF: 11.072; D1
  - Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, Bada-Bosch T, Oppenheimer F, Moreso F, López-Oliva MO, Melilli E, Rodríguez-Ferrero ML, Bravo C, Burgos E, Facundo C, Lorenzo I, Yáñez I, Galeano C, Roca A, Cabello M, Gómez-Bueno M, García-Cosío MD, Graus J, Llado L, de Pablo A, Loinaz C, Aguado B, Hernández D, Domínguez-Gil B. COVID-19 in transplant recipients: The Spanish experience. *Am J Transplant.* 2021; 21(5): 1825-37. Article. IF: 9.369; D1
  - Fernández LM, Sánchez-Álvarez JE, de la Tassa CM, Fernández JJB, María V, Fernández E, Valdvielso JM, Betriu A. Risk factors associated with valvular calcification in patients with chronic kidney disease. Analysis of NEFRONA study. *Nefrología.* 2021; 41(3): 337-46. Article. IF: 3.084; Q2
  - Fernández-Juárez G, Rojas-Rivera J, van de Logt AE, Justino J, Sevillano A, Caravaca-Fontán F, Ávila A, Rabasco C, Cabello V, Varela A, Díez M, Martín-Reyes G, Díezhardino MG, Quintana LF, Agraz I, Gómez-Martino JR, Cao M, Rodríguez-Moreno A, Rivas B, Galeano C, Bonet J, Romero A, Shabaka A, Plaisier E, Espinosa M, Egido J, Segarra A, Lambeau G, Ronco P, Wetzel J, Praga M. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. *Kidney Int.* 2021; 99(4): 986-98. Article. IF: 18.998; D1
  - González-Parra E, Bover J, Herrero J, Sánchez E, Molina P, Martín-Malo A, Rubio MAB, Lloret S, Navarro J, Arenas MD. Control of phosphorus and prevention of fractures in the kidney patient. *Nefrología.* 2021; 41(1): 7-14. Review. IF: 3.084; Q2
  - Heras Benito M, Fernández-Reyes Luis MJ, Martín Varas C, Urzola Rodríguez G. Clinical characteristics of chronic kidney disease (no dialysis) in nonagenarians. *Rev Esp Geriatr Gerontol.* 2021; 56(2): 119-20.. Article. Not Indexed
  - Herzog R, Sacnun JM, González-Mateo G, Barotosa M, Bialas K, Wagner A, Unterwurzacher M, Sobieszek IJ, Daniel-Fischer L, Rusai K, Pascual-Antón L, Kaczirek K, Vychytal A, Schmitt CP, López-Cabrera M, Alper SL, Aufricht C, Kratochwill K. Lithium preserves peritoneal membrane integrity by suppressing mesothelial cell alpha B-crystallin. *Sci Transl Med.* 2021; 13(608): eaaz9705. Article. IF: 19.319; D1
  - Leon LM, García EG, López MO, Afonso S, Santana MJ, Jiménez C. Immunosuppressive drugs and transplantation protocols. *Arch Esp Urol.* 2021; 74(10): 1002-12. Article. IF: 0.43; Q4
  - Maldonado M, Ossorio M, Del Peso G, Santos C, Álvarez L, Sánchez-Villanueva R, Rivas B, Vega C, Selgas R, Bajo MA. COVID-19 incidence and outcomes in a home dialysis unit in Madrid (Spain) at the height of the pandemic. *Nefrología.* 2021; 41(3): 329-36. Article. IF: 3.084; Q2
  - Martín-Moreno PL, Sánchez-Fructuoso Al, Mazuecos A, Mir M, López-López I, González-Rinne A, Coca A, Valero R, Galiano AV, Ridao N, Toapanta-Gaibor NG, Fernández-Tagarro E, Cruzdado-Vega L, Pérez-Mir M, Jiménez C. Paternal safety of the use of mycophenolic acid in kidney transplant recipients. Results of the EMVARON study. *Clin Transplant.* 2021; 35(5): e14256. Article. IF: 3.456; Q2
  - Morelle J, Marechal C, Yu ZZ, Debaix H, Corre T, Lambie M, Verduijn M, Dekker F, Bovy P, Evenepoel P, Bammens B, Selgas R, Bajo MA, Coester AM, Sow A, Hautem N, Struijk DG, Krediet RT, Balligand JL, Goffin E, Crott R, Ripoché P, Davies S, Devuyst O. AQP1 promoter variant, water transport, and outcomes in peritoneal dialysis. *New Engl J Med.* 2021; 385(17): 1570-80. Article. IF: 176.079; D1
  - Paez-Vega A, Cantisan S, Aguera ML, Suner M, Facundo C, Yuste JR, Fernández-Ruiz M, Montejano M, Redondo-Pachón D, López-Oliva MO, Fernández-Rodríguez A, Farinas MC, Hernández D, Len O, Muñoz P, Valle-Arroyo J, Rodelo-Haad C, Cordero E, Torre-Cisneros J. Pretransplant CMV-specific T-cell immunity but not dose of anitihymocyte globulin is associated with recovery of specific immunity after kidney transplantation. *J Infect Dis.* 2021; 223(7): 1205-13. Article. IF: 7.759; Q1
  - Peces R, Mena R, Peces C, Barruz P, Trujillo H, Carrasco A, Espinosa L, Selgas R, Lapunzina P, Nevado J. Historical and geographical distribution of the founder mutation c.610G > A; p.Ala204Thr in the CLCNKB gene linked to Bartter syndrome type III in Spain. *Clin Kidney J.* 2021; 14(8): 1990-3. Letter. IF: 5.86; Q1
  - Peces R, Mena R, Peces C, Cuesta E, Lapunzina P, Selgas R, Nevado J. Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvanoper. *Clin Kidney J.* 2021; 14(8): 1987-9. Letter. IF: 5.86; Q1
  - Pérez-Torres A, García MEG, Ossorio-González M, García LA, Bajo MA, del Peso G, Plaza AC, Selgas R. The effect of nutritional interventions on long-term patient survival in advanced chronic kidney disease. *Nutrients.* 2021; 13(2): 621. Article. IF: 6.706; Q1
  - Pérez-Torres A, Muñoz AC, Arnal LML, Paris AS, Peracho CV, Catala JL, Villanueva RS, Guldris SC, González FT, Pérez AN, Amado AS, García MEG, Cuadrado GB. Multidisciplinary nutritional consensus on assessment and nutritional dietary treatment in patients with chronic kidney disease and SARS-CoV-2 infection. *Nefrología.* 2021; 41(4): 453-60. Article. IF: 3.084; Q2
  - Portoles J, Vega A, Lacoba E, López-Sánchez P, Botella M, Yuste C, Cleary CM, Ballesteros SS, Sanchidrián SG, García LS, Carreno A, Bajo MA, Janeiro D, Tato A, Molano B, Cleary CM, Escrivano A, Vian J, Ballesteros SS, Vega A, Martínez A, Campos J, Bajo MA, del Peso G, Palomares JRR, Carreno A, Felipe C, Perpen A, Hernández MJ, Moreno F, García LS, Gorrín MR, Burguera A, Fernández-Reyes MJ, Rodríguez A, Hevia C, Lorenzo M, Paraiso V, Sanchidrián SG, Tornero F, Hernández E, Ortega M, Gutiérrez BC, Benito J, Ortega O, Herrero JC, Pizarro MS. Is peritoneal dialysis suitable technique CKD patients over 65 years? A prospective multicenter study. *Nefrología.* 2021; 41(5): 529-38. Article. IF: 3.084; Q2
  - Portoles JM, Jiménez C, Janeiro D, López-Oliva MO, Ortega-Carrión A, Blanquez D, Arribas L, Gómez C, Díez T, Pascual J, Portero I. The immunobiogram, a novel in vitro assay to evaluate treatment resistance in patients receiving immunosuppressive therapy. *Front Immunol.* 2021; 11: 618202. Article. IF: 8.786; Q1
  - Rodrigues-Díez RR, Tejera-Muñoz A, Orejudo M, Márquez-Expósito L, Santos L, Rayego-Mateos S, Cantero-Navarro E, Tejedor-Santamaría L, Marchant V, Ortiz A, Egido J, Mezzano S, Selgas R, Navarro-González JF, Valdvielso JM, Lavoz C, Ruiz-Ortega M. Interleukin-17A: Potential mediator and therapeutic target in hypertension. *Nefrología.* 2021; 41(3): 244-57. Review. IF: 3.084; Q2
  - Ruiz-Ruiz Gómez M, Fernández-Ruiz M, Silva JT, Vidal E, Origen J, Calvo-Cano A, Luna-Huerta E, Merino E, Hernández D, Jirona-Gallegos C, Escudero-Sánchez R, Gioia F, Moreno A, Roca C, Cordero E, Janeiro D, Sánchez-Sobrino B, Montero MM, Redondo D, Candel FJ, Pérez-Flores I, Arminanzas C, González-Rico C, Farinas MC, Rodrigo E, Loeches B, López-Oliva MO, Montejo M, Lauzurica R, Horcajada JP, Pascual J, Andres A, Aguado JM, López-Medrano F. Efficacy and safety of oral fosfomycin for asymptomatic bacteriuria in kidney transplant recipients: results from a spanish multicenter cohort. *Antimicrob Agents Ch.* 2021; 65(5): e02267-20. Article. IF: 5.938; Q1
  - Solache-Berrocal G, Rolle-Sonora V, Martín-Fernández N, Cambray S, Valdvielso JM, Rodríguez I. CYP24A1 and KL polymorphisms are associated with the extent of vascular calcification but do not improve prediction of cardiovascular events. *Nephrol Dial Transpl.* 2021; 36(11): 2076-83. Article. IF: 7.186; Q1
  - van Gelder MK, Vollenbroek JC, Lentferink BH, Hazenbrink DHM, Besseling PJ, Simonis F, Giavanela S, Ligabue G, Rubio MBA, Cappelli G, Joles JA, Verhaar MC, Gerritsen KGF. Safety of electrooxidation for urea removal in a wearable artificial kidney is compromised by formation of glucose degradation products. *Artif Organs.* 2021; 45(11): 1422-28. Article. IF: 2.663; Q3
  - Villanego F, Mazuecos A, Pérez-Flores IM, Moreso F, Andres A, Jiménez-Martín C, Molina M, Canal C, Sánchez-Camara LA, Zarraga S, Ruiz-Fuentes MD, Aladrén MJ, Melilli E, López V, Sánchez-Álvarez E, Crespo M, Pascual J. Predictors of severe COVID-19 in kidney transplant recipients in the different epidemic waves: Analysis of the Spanish Registry. *Am J Transplant.* 2021; 21(7): 2573-82. Article. IF: 9.369; D1
  - Zamarrón E, Jaureguizar A, García-Sánchez A, Díaz-Cambriles T, Alonso-Fernández A, Lores V, Mediano O, Rodríguez-Rodríguez P, Cabello-Pelegrín S, Morales-Ruiz E, Ramirez-Prieto MT, Valiente-Díaz MI, Gómez-García T, García-Río F. Obstructive sleep apnea is associated with



impaired renal function in patients with diabetic kidney disease. *Sci Rep-Uk.* 2021; 11(1): 5675. Article. IF: 4.996; Q2

## ■ Research projects

**Bajo Rubio MA.** Abordaje nutricional en pacientes con enfermedad renal. Fresenius Kabi España S.A.U. 2021-Ongoing.

Management centre: FIBHULP

**Bajo Rubio MA.** Biopsia líquida en diálisis peritoneal: correlación biopsia / efluente peritoneal (PI18/00882). ISCIII. 2019-2023.

Management centre: FIBHULP

**Bajo Rubio MA.** Clinical validation of a continuous flow peritoneal dialysis system, with dialysate regeneration (CORN-DIAL). UE. 2020-2024.

Management centre: FIBHULP

**Bajo Rubio MA.** Las células mesoteliales del efluente crecidas ex vivo reflejan las alteraciones peritoneales encontradas en la biopsia peritoneal. Oportunidades adicionales para biomarcadores en el efluente. Fundación SENEFRO. 2016-Ongoing.

Management centre: FIBHULP

**Jiménez Martín C.** Desarrollo y aplicación de un programa grupal de atención psicológica basada en las preferencias y valores con el objetivo de mejora de resultados en salud en el paciente con trasplante renal. Astellas Pharma S.A.

2018-Ongoing.

Management centre: FIBHULP

**Jiménez Martín C.** Evaluación de la microcirculación cortical (MCC) del trasplante renal a largo plazo medida por eco-grafía con contraste (EC) y su correlación histopatológica por biopsia renal. Sociedad Madrileña de Trasplantes. 2019-On-going.

Management centre: FIBHULP

**Sánchez Villanueva R.** Creación de un centro de referencia para el estudio de los mecanismos implicados en las reacciones de hipersensibilidad a las membranas de hemodialisis basadas en polysulfona. Ni-pro Europe Nv. 2017-Ongoing.

Management centre: FIBHULP

## ■ Cibers & Retics

**Bajo Rubio MA.** Red de Investigación Renal. (RD16/0009/0008). ISCIII. (31/12/2022).

Management centre: FIBHULP

**Bajo Rubio MA.** Red de Investigación Renal. (RD21/0005/0018). ISCIII. (31/12/2024).

Management centre: FIBHULP

## ■ Clinical trials

**Bajo Rubio, MA.** Respuesta inmune y seguridad de la vacunación COVID-19 en

pacientes con erc avanzada, en diálisis y trasplantados renales.

Type: Estudios, fase EPA-OD.

HULP code: PI-4709 SENCOVAC.

Sponsored by: Grupo Español De Estudio De La Nefropatía Diabética.

Signed date: 05/03/2021

**Jiménez Martín, C.** Estudio en fase II, abierto, aleatorizado y de varias cohortes para evaluar la eficacia, la seguridad y la farmacocinética preliminares de bivv020 para la prevención y el tratamiento del rechazo mediado por anticuerpos en adultos receptores de trasplante renal.

Type: Clinical Trials, phase II.

HULP code 5940 ACT17012.

Sponsored by: Sanofi-Aventis Recherche & Developpement.

Signed date: 29/10/2021

## ■ Patents and trademarks

**Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz Al, Álvarez Builla J, Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R,** inventors; FIBHULP, Universidad de Alcalá, assignees. Use of compounds derived from salts of pyridazine[1',6':1,2]pyrido[3,4-b]indolinium as anti-inflammatory agents. P201331143, PCT/ES2014/070603; 2013 July 25.

**Selgas Gutiérrez R, Bellón Heredia T, Rodríguez Sanz Al, Álvarez Builla J,**

**Vaquero López JJ, Sánchez Alonso P, Alajarín Fernández R,** inventors; FIBHULP, Universidad de Alcalá, assignees.

Use of compounds derived from salts of pyridazine[3,2-b]benzimidazolium as anti-inflammatory agents. P201430411, PCT/ES2014/070603; 2013 July 25.

**Aguilera Peralta Al, López-Cabrera M, Selgas Gutiérrez R, Steppan S, Passlickdeetjen J,** inventors; Fresenius Medical Care Deutschland GmbH, assignee. Pharmaceutical compositions containing steviosides. EP14191301.2, PCT/EP2015/074955, CN107073022, US10213452; 2014 October 31.

**López-Cabrera M, Aguilera Peralta Al, Selgas Gutiérrez R, Passlickdeetjen J, Buechel J, Steppan S,** inventors; Fresenius Medical Care AG & Co. KGaA, assignee. Method and kit for diagnosing epithelial to mesenchymal transition of the peritoneum (EMT-Chip). DE102015115158.8, PCT/EP2016/071149, CN108449998B, EP3347715B1, ES2833553T3, JP6869963B2, US2018246098A1; 2015 September 09.

**Sánchez Niño MD, Ortiz Arduán A;** FIBHULP, Instituto de Investigación Sanitaria Fundación Jiménez Díaz. Pharmaceutical composition and its use in the manufacture of a medicament for treating chronic kidney disease and method for selecting compounds. P201430081, PCT/ES2015/070039; 2014 January 27.